Aptamer-linked antibody enonomers extend serum half-life, disrupt receptor multimers, and target drug-resistant HER2 and ovarian cancer cells.
Small artificial RNA raises protein expression by methylating target mRNA polyA tails, delaying deadenylation without genome editing.
Direct anticoagulant aptamers inhibit coagulation steps during ECMO to sustain control for hours while reducing bleeding and monitoring burden.
Modular promoters, introns, leaders, and 3' UTRs enable precise gene expression control in transgenic plants for targeted phenotype modification.